Sanofi and Translate Bio Initiate P-I/II Study of MRT5500 Against COVID-19

 Sanofi and Translate Bio Initiate P-I/II Study of MRT5500 Against COVID-19

Sanofi and Translate Bio Initiate P-I/II Study of MRT5500 Against COVID-19

Shots:

  • The companies reported the initiation of P-I/II trial to evaluate the safety, tolerability, and immunogenicity of MRT5500 (1 or 2doses given 21 days apart) vs PBO in ~415 healthy adults aged ≥18yrs. with its expected interim results in Q3’21
  • The study will evaluate three different dose levels of MRT5500 (15/45/135µg). The preclinical data of MRT5500 showed induction of high neutralizing antibody levels in two immunizations of the mRNA vaccine are comparable to the upper range in infected humans
  • The ongoing preclinical studies will continue to evaluate MRT5500 as well as additional mRNA candidates against emerging SARS-CoV-2 variants

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post